Dr. Seth A. Wander, MD,PHD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Miami, Lm Miller School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 403
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Miami, Lm Miller School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MA license 266155
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- North Shore Medical Center - Salem, MA
- Nantucket Cottage Hospital Nantucket, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
- Nantucket Cottage Hospital (87 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 403
- Services billed
- 1,473
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 328 | 210 |
| Established patient office or other outpatient visit, 40-54 minutes | 276 | 167 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 162 | 60 |
| Telephone medical discussion with physician, 21-30 minutes | 45 | 37 |
| Hospital discharge day management, more than 30 minutes | 24 | 22 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 20 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Boston, MA | 271 |
| Anastrozole Other prescribers in Boston, MA | 71 |
| Exemestane | 49 |
| Verzenio (abemaciclib) | 25 |
| Tamoxifen Citrate Other prescribers in Boston, MA | 18 |
| Orserdu (elacestrant hcl) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 76 payments worth $108,445 in total to this clinician.
| Lilly USA, LLC | $23,200 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $21,236 |
| Stemline Therapeutics Inc. | $19,894 |
| Novartis Pharmaceuticals Corporation | $13,060 |
| Pfizer Inc. | $11,866 |
| Tersera Therapeutics LLC | $8,747 |
| Eli Lilly and Company | $2,752 |
| Delcath Systems | $2,500 |
| Consulting Fee | $97,140 |
|---|---|
| Food and Beverage | $4,306 |
| Travel and Lodging | $3,549 |
| Compensation for services other than consulting (speaking, faculty) | $2,200 |
| Honoraria | $1,250 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $8,400 |
| AstraZeneca Pharmaceuticals LP Sep 17, 2025 | Consulting Fee | $5,740 |
| Novartis Pharmaceuticals Corporation Oct 29, 2025 | Consulting Fee KISQALI · Oncology | $5,475 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee Truqap · Oncology | $4,920 |
| AstraZeneca Pharmaceuticals LP Dec 10, 2025 | Consulting Fee ENHERTU · Oncology | $4,920 |
| Stemline Therapeutics Inc. Nov 7, 2025 | Consulting Fee Orserdu · Oncology | $4,680 |
| Novartis Pharmaceuticals Corporation Nov 21, 2025 | Consulting Fee KISQALI · Oncology | $4,200 |
| Stemline Therapeutics Inc. Oct 28, 2025 | Consulting Fee Orserdu · Oncology | $3,900 |
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $3,600 |
| Lilly USA, LLC Feb 18, 2025 | Consulting Fee VERZENIO · Oncology | $3,600 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Stemline Therapeutics Inc. Dec 26, 2025 | Consulting Fee Orserdu · Oncology | $3,120 |
| Stemline Therapeutics Inc. Dec 26, 2025 | Consulting Fee Orserdu · Oncology | $3,120 |
| Stemline Therapeutics Inc. Dec 26, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee Truqap · Oncology | $4,920 |
| Pfizer Inc. Dec 19, 2025 | Consulting Fee | $1,440 |
| AstraZeneca Pharmaceuticals LP Dec 10, 2025 | Consulting Fee ENHERTU · Oncology | $4,920 |
| Puma Biotechnology, Inc. Dec 9, 2025 | Consulting Fee | $1,600 |
| Veracyte, Inc. Dec 3, 2025 | Honoraria | $1,250 |
| Novartis Pharmaceuticals Corporation Nov 21, 2025 | Consulting Fee KISQALI · Oncology | $4,200 |
| Stemline Therapeutics Inc. Nov 7, 2025 | Consulting Fee Orserdu · Oncology | $4,680 |
| Novartis Pharmaceuticals Corporation Oct 29, 2025 | Consulting Fee KISQALI · Oncology | $5,475 |
| Stemline Therapeutics Inc. Oct 28, 2025 | Consulting Fee Orserdu · Oncology | $3,900 |
| Novartis Pharmaceuticals Corporation Oct 22, 2025 | Travel and Lodging KISQALI · Oncology · travel to East Hanover, NJ | $69.00 |
| Tersera Therapeutics LLC Oct 13, 2025 | Consulting Fee Margenza · Oncology | $1,500 |
| Novartis Pharmaceuticals Corporation Oct 4, 2025 | Travel and Lodging KISQALI · Oncology · travel to East Hanover, NJ | $293 |
| Novartis Pharmaceuticals Corporation Oct 4, 2025 | Travel and Lodging KISQALI · Oncology · travel to East Hanover, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation Oct 3, 2025 | Travel and Lodging travel to Whippany, NJ · in-kind | $404 |
| Delcath Systems Oct 1, 2025 | Consulting Fee Hepzato Kit · Oncology | $2,500 |
| Tersera Therapeutics LLC Sep 26, 2025 | Consulting Fee Zoladex · Oncology | $2,000 |
| Tersera Therapeutics LLC Sep 26, 2025 | Travel and Lodging Zoladex · Oncology · travel to Chicago, IL · in-kind | $270 |
| Tersera Therapeutics LLC Sep 26, 2025 | Travel and Lodging Zoladex · Oncology · travel to Chicago, IL | $220 |
| AstraZeneca UK Limited Sep 18, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,640 |
| AstraZeneca Pharmaceuticals LP Sep 17, 2025 | Consulting Fee | $5,740 |
| Pfizer Inc. Aug 28, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,500 |
| Stemline Therapeutics Inc. Aug 22, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| Eli Lilly and Company Aug 8, 2025 | Consulting Fee VERZENIO · Oncology | $400 |
| Stemline Therapeutics Inc. Aug 1, 2025 | Consulting Fee Orserdu · Oncology | $3,120 |
| Stemline Therapeutics Inc. Jun 21, 2025 | Travel and Lodging Orserdu · Oncology · travel to Dallas, TX · in-kind | $239 |
| Pfizer Inc. Jun 11, 2025 | Consulting Fee | $1,950 |
| Pfizer Inc. Jun 11, 2025 | Consulting Fee | $650 |
| Tersera Therapeutics LLC May 31, 2025 | Consulting Fee Zoladex · Oncology | $3,000 |
| Tersera Therapeutics LLC May 31, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA | $148 |
| Pfizer Inc. May 28, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $3,575 |
| Pfizer Inc. May 28, 2025 | Consulting Fee TUKYSA · ONCOLOGY | $2,275 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $406 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $67.14 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $46.62 |
| Stemline Therapeutics Inc. May 15, 2025 | Travel and Lodging Orserdu · Oncology · travel to Boston, MA · in-kind | $382 |
| Pfizer Inc. May 15, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $188 |
| Dr.reddy's Laboratories,inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $700 |
| Tersera Therapeutics LLC Mar 14, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $588 |
| Novartis Pharmaceuticals Corporation Mar 7, 2025 | Consulting Fee KISQALI · Oncology | $2,100 |
| Lilly USA, LLC Feb 18, 2025 | Consulting Fee VERZENIO · Oncology | $3,600 |
| AstraZeneca Pharmaceuticals LP Feb 7, 2025 | Consulting Fee | $2,055 |
| Lilly USA, LLC Feb 5, 2025 | Consulting Fee VERZENIO · Oncology | $3,600 |
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $8,400 |
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $3,600 |
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $2,000 |
| Lilly USA, LLC Feb 4, 2025 | Consulting Fee VERZENIO · Oncology | $2,000 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $440,006 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)
Genentech, Inc. - Morpheus Breast Cancer
Hoffmann-la Roche Limited - Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05169567 - A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Stemline Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.